Fig. 6: CLL1CART with TRAC-KO (CLL-1 KO) is effective against the HM5896 PDX model.
From: Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia
A Schematic of the murine trial design with injection of 1e6 and later 10e6 CAR or UTD T cells. B Flow cytometric assessment of JMML burden in PB over time. p-values: d33 CLL-1 KO vs. PBS = 0.0452; d61 CLL-1 KO vs. UTD KO = 0.0268, CLL-1 KO vs. PBS = 0.0114. C Flow cytometric assessment of leukemia burden in different tissues upon termination. p-values: BM [e6] CLL-1 KO vs. UTD KO = 0.0009; spleen [%] CLL-1 KO vs. UTD KO = 0.0046; spleen [e6] CLL-1 KO vs. UTD KO = 0.0011; cardiac blood CLL-1 KO vs. UTD KO = 0.0104; ****<0.0001. D Flow cytometric assessment of stem cell amount by staining for CD34 in different tissues upon termination. p-values: BM/spleen CLL-1 KO vs. PBS = 0.0019/0.0004; ****<0.0001. E, F Flow cytometric analysis subsetting cells from (D) into CD34+CD38+ cells (E) and CD34+CD38− cells (F). p-values E BM CLL-1 KO vs. PBS = 0.0023; spleen CLL-1 KO vs. UTD KO = 0.0001, CLL-1 KO vs. PBS = 0.0010; F BM [#] CLL-1 KO vs. UTD KO = 0.0035; spleen [%] CLL-1 KO vs. PBS = 0.0006; spleen [#] CLL-1 KO vs. UTD KO = 0.0019; ****<0.0001. n = 7 mice for CLL-1 KO and UTD KO (CLL-1 or UTD with TRAC-KO), n = 5 for PBS. Statistical analysis for (A–F) was performed by one-way ANOVA with Tukey’s multiple comparisons test. d day.
